Gerald would be foolish to partner on any of the MANF indications yet. He can partner with the other assets, but not his core asset. After Retinitis completes it's phase 1/2 trial, then a partner will pony up the kind of money Gerald is looking for. That won't happen in my opinion for another 1.5 to 2 years for Retinitis.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links